Abstract | AIM: METHODS: We followed people enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort from outpatient hospital clinics and general practices throughout Denmark in 2010-2013. We used Poisson regression to compute age- and gender-adjusted risk ratios (RRs). RESULTS: Among 1158 new Type 2 diabetes mellitus patients, 302 (26%) did not receive glucose-lowering therapy within the first year, 723 (62%) received monotherapy [685 (95%) with metformin], and 133 (12%) received more than one drug. Predictors of receiving any vs. no therapy and combination vs. monotherapy were: age < 40 years [RR: 1.29 (95% CI: 1.16-1.44) and 3.60 (95% CI: 2.36-5.50)]; high Charlson Comorbidity Index [RRs: 1.20 (95% CI: 1.05-1.38) and 2.08 (95% CI: 1.16-3.72)]; central obesity [RRs: 1.23 (95% CI: 1.04-1.44) and 1.93 (95% CI: 0.76-4.94)]; fasting blood glucose of ≥ 7.5 mmol/l [RRs: 1.25 (95% CI: 1.10-1.42) and 1.94 (95% CI: 1.02-3.71)]; and HbA1c ≥ 59 mmol/mol (≥ 7.5%) [RR: 1.26 (95% CI: 1.20-1.32) and 2.86 (95% CI: 1.97-4.14)]. Weight gain ≥ 30 kg since age 20, lack of physical exercise and C-peptide of < 300 pmol/l also predicted therapy. CONCLUSIONS:
|
Authors | A Mor, K Berencsi, E Svensson, J Rungby, J S Nielsen, S Friborg, I Brandslund, J S Christiansen, A Vaag, H Beck-Nielsen, H T Sørensen, R W Thomsen |
Journal | Diabetic medicine : a journal of the British Diabetic Association
(Diabet Med)
Vol. 32
Issue 12
Pg. 1546-54
(Dec 2015)
ISSN: 1464-5491 [Electronic] England |
PMID | 26032247
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 The Authors. Diabetic Medicine © 2015 Diabetes UK. |
Chemical References |
- Hypoglycemic Agents
- Metformin
|
Topics |
- Adult
- Age Factors
- Aged
- Body Mass Index
- Cohort Studies
- Denmark
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy)
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- General Practitioners
- Hospitalists
- Humans
- Hyperglycemia
(prevention & control)
- Hypoglycemic Agents
(therapeutic use)
- Male
- Metformin
(therapeutic use)
- Middle Aged
- Obesity, Abdominal
(complications)
- Outpatient Clinics, Hospital
- Practice Patterns, Physicians'
- Prospective Studies
- Registries
|